Cetera Investment Advisers Sells 59,212 Shares of Haleon plc (NYSE:HLN)

Cetera Investment Advisers trimmed its holdings in Haleon plc (NYSE:HLN) by 25.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 174,576 shares of the company’s stock after selling 59,212 shares during the quarter. Cetera Investment Advisers’ holdings in Haleon were worth $1,442,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Clearbridge Investments LLC increased its position in Haleon by 44.6% in the first quarter. Clearbridge Investments LLC now owns 38,446,978 shares of the company’s stock worth $326,415,000 after purchasing an additional 11,865,076 shares during the period. Wellington Management Group LLP increased its position in Haleon by 164.6% in the fourth quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after purchasing an additional 8,423,475 shares during the period. Martin Investment Management LLC increased its position in Haleon by 12,018.4% in the first quarter. Martin Investment Management LLC now owns 4,463,205 shares of the company’s stock worth $37,893,000 after purchasing an additional 4,426,375 shares during the period. Sculptor Capital LP increased its position in Haleon by 67.8% in the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after purchasing an additional 3,592,000 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in Haleon by 95.5% in the second quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock worth $16,143,000 after purchasing an additional 954,622 shares during the period. 6.67% of the stock is owned by institutional investors.

Haleon Stock Down 0.8 %

HLN opened at $10.02 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock’s fifty day simple moving average is $10.19 and its 200 day simple moving average is $9.11. Haleon plc has a 1-year low of $7.70 and a 1-year high of $10.80. The stock has a market cap of $45.75 billion, a PE ratio of 33.40, a price-to-earnings-growth ratio of 2.93 and a beta of 0.26.

Haleon (NYSE:HLN) last released its earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. Haleon had a return on equity of 13.15% and a net margin of 9.71%. During the same period last year, the company posted $0.08 earnings per share. As a group, research analysts expect that Haleon plc will post 0.47 earnings per share for the current year.

Haleon Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Investors of record on Friday, August 16th were given a dividend of $0.0514 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio is currently 33.33%.

Analysts Set New Price Targets

A number of brokerages recently commented on HLN. Berenberg Bank began coverage on Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating for the company. Morgan Stanley lifted their price objective on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Haleon presently has an average rating of “Buy” and an average target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.